Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult ewing sarcoma patients treated with chemotherapy

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 2963-2970

  de Groot, Stefanie ^a   Gelderblom, Hans ^a   Fiocco, Marta ^a,b   Vmgbovée, Judith ^a   van der Hoeven, Jacobus J M ^a   Pijl, Hanno ^a   Kroep, Judith R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Chemotherapy; Ewing sarcoma; IGF 1; IGF 1R; IGF 2; IGF BP3; Survival

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; VINCRISTINE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85020920021     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S123726     Document Type: Article

References (48)

1. Ladenstein R, Potschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284-3291.
2. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425-430.
3. Benini S, Zuntini M, Manara MC, et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing’s sarcoma. Int J Cancer. 2006;119(5):1039-1046.
4. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24(16):7275-7283.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3-34.
6. van Maldegem AM, Bovee JV, Peterse EF, Hogendoorn PC, Gelderblom H. Ewing sarcoma: the clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. Eur J Cancer. 2016;53:171-180.
7. Renehan AG, Zwahlen M, Minder C, O’dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353.
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
9. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene. 2005;363:1-14.
10. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev. 1996;76(4):1005-1026.
11. Ho AL, Schwartz GK. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol. 2011;29:4581-4583.
12. Chaves J, Saif MW. IGF system in cancer: from bench to clinic. Anticancer Drugs. 2011;22(3):206-212.
13. Iams WT, Lovly CM. Molecular pathways: clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade. Clin Cancer Res. 2015;21(19):4270-4277.
14. Van der Woude HJ, Bloem JL, Taminiau AH, Nooy MA, Hogendoorn PC. Classification of histopathologic changes following chemotherapy in Ewing’s sarcoma of bone. Skeletal Radiol. 1994;23(7):501-507.
15. Van der Woude HJ, Bloem JL, Holscher HC, et al. Monitoring the effect of chemotherapy in Ewing’s sarcoma of bone with MR imaging. Skeletal Radiol. 1994;23(7):493-500.
16. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.
17. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712-1721.
18. Friedrich N, Wolthers OD, Arafat AM, et al. Age-and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99(5):1675-1686.
19. Rafferty B, Rigsby P, Gaines-Das RE. Multicentre collaborative study to calibrate IGF-II by bioassay and immunoassay: establishment of the First WHO Reference Reagent. Growth Horm IGF Res. 2001;11(1):18-23.
20. Contal C, O’Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30(3):253-270.
21. Tunes-da-Silva G, Klein JP. Cutpoint selection for discretizing a continuous covariate for generalized estimating equations. Comput Stat Data Anal. 2011;55(1):226-235.
22. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
23. The Comprehensive R Archive Network [homepage on the Internet]. Available from cran.r-project.org/. 2015. Accessed March 3, 2016.
24. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114.
25. Schumacher B, Garinis GA, Hoeijmakers JH. Age to survive: DNA damage and aging. Trends Genet. 2008;24(2):77-85.
26. Scotlandi K, Manara MC, Serra M, et al. Expression of insulin-like growth factor system components in Ewing’s sarcoma and their association with survival. Eur J Cancer. 2011;47(8):1258-1266.
27. Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer. 2001;92(11):2941-2947.
28. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res. 2012;18(14):3992-3997.
29. Elmashad N, Ibrahim WS, Mayah WW, et al. Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16(2):613-619.
30. Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011;29(29):3892-3899.
31. Tas F, Karabulut S, Bilgin E, Tastekin D, Duranyildiz D. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer. Tumour Biol. 2014;35(9):9303-9309.
32. Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol. 2014;35(4):3125-3132.
33. Cho EJ, Lee JH, Yoo JJ, et al. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study. Clin Cancer Res. 2013;19(15):4218-4227.
34. Gallego R, Codony-Servat J, Garcia-Albeniz X, et al. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr Relat Cancer. 2009;16(1):311-317.
35. Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF, Chou CY. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 2014;21(2):217-229.
36. Watanabe S, Tamura T, Ono K, et al. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail. 2010;12(11):1214-1222.
37. Jia T, Gama AT, Heimburger O, et al. IGF-1 and survival in ESRD. Clin J Am Soc Nephrol. 2014;9(1):120-127.
38. Borinstein SC, Barkauskas DA, Krailo M, et al. Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children’s Oncology Group. Cancer. 2011;117(21):4966-4976.
39. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest. 1990;86(6):1806-1814.
40. Yee D, Paik S, Lebovic GS, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989;3(3):509-517.
41. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 1996;56(20):4570-4574.
42. Scartozzi M, Mandolesi A, Giampieri R, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 2010;127(8):1941-1947.
43. de Groot S, Charehbili A, van Laarhoven HW, et al. Insulin-like growth factor 1 receptor expression and IGF1R 3129G. T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Res. 2016;18(1):3.
44. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, et al. Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. PLoS One. 2015;10(2):e0117745.
45. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res. 2003;35(11-12):726-733.
46. Kümmel S, Eggemann H, Luftner D, et al. Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes. Int J Biol Markers. 2007;22(3):186-193.
47. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013;20(6):R321-R339.
48. Steigen SE, Schaeffer DF, West RB, Nielsen TO. Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol. 2009;22(7):914-921.